MoonLake Immunotherapeutics MLTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $54.52M+49.5% | $56.01M+38.8% | $60.64M+69.7% | $49.76M+110% | $36.46M+180% | ||
| $70.02M+47.5% | $65.22M+31.5% | $71.43M+65.7% | $60.7M+98.5% | $47.49M+140% | ||
| $70.02M+47.5% | $65.22M+31.5% | $71.43M+65.7% | $60.7M+98.5% | $47.49M+140% | ||
| $622K+307% | $248K+505% | $115K+25.0% | $95K+20.3% | $153K+119% | ||
| -$69.71M-74.5% | -$62.43M-36.9% | -$69.73M-97.0% | -$55.22M-128% | -$39.94M-192% | ||
| -$0.98-55.6% | -$0.92-27.8% | -$1.10-96.4% | -$0.87-123% | -$0.63-186% | ||
| 71.3M+12.7% | 64.5M+2.5% | 63.4M+0.8% | 63.3M+0.6% | 63.2M+1.0% | ||
| 71.3M+12.7% | 64.5M+2.5% | 63.4M+0.8% | 63.3M+0.6% | 63.2M+1.0% | ||
| -$69.99M-64.4% | -$62.11M-43.0% | -$69.97M-95.3% | -$57.09M-141% | -$42.56M-217% | ||
| $7.12M+558% | —— | $12.86M+510% | -$1.81M-207% | -$1.56M+44.6% | ||
| $10.1M+3,800% | -$3.86M-172% | -$274K— | $3.84M-53.0% | -$273K-133% | ||
| $30.64M-58.1% | $72.4M+47,844% | $480K+162% | $0— | $73.12M+43.4% | ||
| $98K-99.8% | —— | $88.4M— | $88.25M+201% | $56.25M+295% | ||
| -$66.29M-73.8% | -$58.79M-21.3% | -$44.54M-76.2% | -$54.53M-95.5% | -$38.14M-155% | ||
| -$359K-478% | $525K— | $8K+107% | $13K+117% | $95K+17.3% | ||
| $77K+103% | -$203K-109% | -$255K+21.5% | -$1.91M-393% | -$2.76M-1,614% | ||
| -$282K+89.4% | $0-100% | -$247K+44.0% | -$1.9M-429% | -$2.66M-1,112% | ||
| $3.21M-54.8% | $4.44M+37.7% | $4.05M-42.8% | $6.78M+14.9% | $7.1M+20.0% | ||
| -$69.18M-46.9% | -$64.47M-31.0% | -$70.69M-65.3% | -$59.96M-98.3% | -$47.11M-142% | ||
| -$70.02M-47.5% | -$65.22M-31.5% | -$71.43M-65.7% | -$60.7M-98.5% | -$47.49M-140% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does MoonLake Immunotherapeutics's income statement data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.